SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

: Emerging Challenges in Primary Care 2018 Virtual
Activity/Course #:
: 06.23.18PC Virtual
: Free
Release/Start Date:
: Jun 23 2018
Expiration Date:
: Jun 23 2018
: Primary Care Medicine
Target Audience:
: Primary Care Providers
: Live EC Primary Care
Estimated Time To Complete CME Activity:
: 6.0 hours
: 6.0 AMA PRA Category I Credit(s)
6.0 AANP Contact hour(s) which includes 2.75 pharmacology hour(s)
Hardware/Software Requirements:

There is no registration fee for this  CME live virtual Conference!

June 23, 2018
Broadcast Live from Ft. Lauderdale, FL
Start Time: 9:00 AM

Program Summary

Primary care providers face complex challenges everyday in their busy practices. With rapid changes in medicine, staying informed about new developments can be equally challenging. Our goal in this CME activity is to help you hone your skills in the diagnosis and management of patients with varied conditions you are likely encountering in your practice.

We have recruited a faculty of well-known thought leaders and experienced teachers who, as clinicians themselves, understand the challenges you face every day as a primary care provider. Our faculty will be at your disposal to provide evidence-based science, current treatment guidelines, discuss challenging cases, and provide answers for you that can ultimately lead to better health care for your patients. The presentations will include several interactive cases and discussion sessions to keep you actively learning.

Please join us and become an active participant in this one-day learning community of your peers.

Learning Objectives

  1. Recognize the pathogenesis of type 2 diabetes (T2DM) as a progressive, multi-defect disorder; Discuss the strengths and limitations of current guidelines for diabetes management; Successfully use strategies for adherence to multiple medications to improve outcomes in diabetes; Examine data on current combination strategies to choose therapies that most effectively address a patient’s underlying pathophysiologic needs.

  2. Discuss clinician and patient barriers to initiation and intensification of insulin therapy; Recognize the prevalence and clinical impact of hypoglycemia in special populations at risk; Discuss the pharmacology and clinical differences between existing and new long-acting and concentrated insulins; Discuss how to incorporate new basal and concentrated insulins into clinical practice while minimizing the risk of adverse events.

  3. Describe the newer concepts in the pathophysiology of asthma and type 2 inflammation, and the implications of biologic therapies in the era of precision medicine; Determine the utility of simple biomarkers to identify patients who are candidates for targeted biologic therapies and appropriate referral; Discuss the impact of comorbid conditions on asthma control and the evidence-based approach to their treatment; Discuss the paradigms of multidisciplinary care in asthma, with an emphasis on patient and provider education, to improve adherence to inhalers and emerging biologic therapies in asthma.

  4. Review and characterize the clinical features of atopic dermatitis (AD); Discuss the current immuno-pathophysiology of AD; Identify strategies for comprehensive treatment of atopic dermatitis in pediatric and adult populations; Update and position emerging topical therapies as well as up and coming targeted biologic agents as a new treatment category for AD.

  5. Review the risk factors and classification of pulmonary hypertension (PH); Discuss the appropriate diagnostic strategy for pulmonary arterial hypertension (PAH), including the roles of echocardiography, ventilation/perfusion (V/Q) scanning, and right heart catheterization (RHC); Review current and emerging treatments for patients with PAH; Describe how to monitor patients with PAH for disease progression.



Welcome Remarks
Gregg Sherman, MD


The Progression of Type 2 Diabetes: A Rational Approach for Long Term Disease Management
Mark Stolar, MD and Gregg Sherman, MD

 10:25-11:35Safely Achieving Goals in Type 2 Diabetes (T2DM): The Role of Concentrated and Long-
Acting Insulins

Mark Stolar, MD and Deborah Paschal, CRNP




The Role of Type 2 Inflammation in Severe Persistent Asthma: Integrating Biologic
Therapy to Optimize Outcomes
Sandra G. Adams, MD, MS
and Gregg Sherman, MD




Atopic Dermatitis: New Insights, New Therapies
Brad P. Glick, DO, MPH, FAOCD  and Deborah Paschal, CRNP


Evolving Strategies of Care in Pulmonary Arterial Hypertension: Integrating the Data into
Franck Rahaghi, MD, MHS, FCCP and Gregg Sherman, MD


Program Summary and Closing Remarks
Gregg Sherman, MD


*Agenda subject to change.



Sandra G. Adams, MD, MS
Professor, Division of Pulmonary Diseases and Critical Care Medicine
UT Health San Antonio
Staff Physician, The South Texas Veterans Health Care System
Founder, President
WipeDiseases Foundation
San Antonio, TX

Brad P. Glick, DO, MPH, FAOCD
Director, South Florida Psoriasis Treatment Centers
Clinical Assistant Professor of Dermatology
FIU Herbert Wertheim College of Medicine
Miami, FL

Deborah Paschal, CRNP
Clinical Nurse Practitioner
Philadelphia, PA

Franck Rahaghi, MD, MHS, FCCP
Director of Advanced Lung Disease Clinic
Director, Pulmonary Hypertension Clinic
Chairman, Dept. of Pulmonary and Critical Care
Cleveland Clinic Florida
Weston, FL

Mark Stolar, MD
Associate Professor of Clinical Medicine
Northwestern University Medical School
Chicago, IL

Planning Committee

Gregg Sherman, MD
Chief Medical Officer/Course Director
National Association for Continuing Education
Plantation, FL

Sheila Lucas, CWEP
Activity Director
National Association for Continuing Education
Plantation, FL

Sandy Bihlmeyer, M.Ed.
National Association for Continuing Education

Plantation, FL

Michelle Frisch, MPH, CHCP
National Association for Continuing Education
Plantation, FL

Harvey C. Parker, Ph.D., CHCP
National Association for Continuing Education
Plantation, FL


Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 6 Contact hour(s) of continuing education including 2.75 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the accredited providers are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosure will be provided in the activity materials.
Commercial Support
This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., an educational grant from AstraZeneca Pharmaceuticals LP, an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals, an educational grant from Novo Nordisk Inc, and an educational grant from Lilly. For further information concerning Lilly grant funding visit